Results 101 to 110 of about 14,491 (226)

Impact of Long‐Term Structured Exercise on Body Composition in an NTRK Fusion‐Positive NSCLC Patient Treated With Entrectinib

Thoracic Cancer, Volume 16, Issue 23, December 2025.
A 42‐year‐old NTRK‐positive NSCLC patient on entrectinib completed a 2‐year supervised exercise program. Regular aerobic and resistance training safely mitigated entrectinib‐induced weight gain, preserved lean mass, improved functional capacity, and enhanced quality of life.
Alice Avancini, Marco Sposito, Gloria Adamoli, Anita Borsati, Christian Ciurnelli, Ilaria Mariangela Scaglione, Serena Eccher, Linda Toniolo, Daniela Tregnago, Lucia Longo, Jessica Insolda, Michele Milella, Federico Schena, Sara Pilotto, Lorenzo Belluomini   +14 more
wiley   +1 more source

The paradox of cancer genes in non-malignant conditions: implications for precision medicine. [PDF]

, 2020
Next-generation sequencing has enabled patient selection for targeted drugs, some of which have shown remarkable efficacy in cancers that have the cognate molecular signatures.
Adashek, Jacob J, Kato, Shumei, Kurzrock, Razelle, Lippman, Scott M   +3 more
core  

Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non‐EML4‐ALK rearrangements detected from cerebrospinal fluid: A case report

Thoracic Cancer, 2020
A 47‐year‐old female with ALK‐rearranged lung adenocarcinoma developed leptomeningeal metastasis (LM) after progression on first‐line crizotinib. Alectinib 300 mg was commenced and the patient achieved clinical and radiographic improvements.
Zhaona Li, Pupu Li, Bing Yan, Qiongqiong Gao, Xiangli Jiang, Zhongli Zhan, Qingna Yan, Analyn Lizaso, Chun Huang   +8 more
doaj   +1 more source

Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis

BMC Cancer
Objectives To compare the efficacy, safety and effects on quality of life of different ALK-inhibitors for global and Asian patients with advanced ALK-positive non-small-cell lung cancer (NSCLC).
Mingye Zhao, Taihang Shao, Hanqiao Shao, Caicun Zhou, Wenxi Tang   +4 more
doaj   +1 more source

Evaluation of Solubility, Dissolution Rate, and Oral Bioavailability of β-Cyclodextrin and Hydroxypropyl β-Cyclodextrin as Inclusion Complexes of the Tyrosine Kinase Inhibitor, Alectinib

Pharmaceuticals
This study aims to improve the solubility and dissolution rate of alectinib (ALB), a tyrosine kinase inhibitor commonly used for treating non-small-cell carcinoma (NSCLC).
Bashar J M Majeed, Mohammed A. Saadallah, I. Al-Ani, Mohamed El-Tanani, K. A. Al Azzam, Hassan H. Abdallah, Feras Al-Hajji   +6 more
semanticscholar   +1 more source

Alectinib vs. Lorlatinib in the Front-Line Setting for ALK-Rearranged Non-Small-Cell Lung Cancer (NSCLC): A Deep Dive into the Main Differences across ALEX and CROWN Phase 3 Trials

Cancers
Simple Summary This study is an analytic review of the data on the two most used ALK TKIs, alectinib and lorlatinib, used as the first treatment for ALK-positive NSCLC.
I. Attili, Valeria Fuorivia, G. Spitaleri, C. Corvaja, P. Trillo Aliaga, E. Del Signore, Riccardo Asnaghi, A. Carnevale Schianca, A. Passaro, Filippo de Marinis   +9 more
semanticscholar   +1 more source

Alectinib in Early-Stage Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Current Evidence and Future Challenges

Cancers
Simple Summary The tyrosine kinase inhibitor alectinib is currently the first-line treatment for advanced ALK-positive non-small cell lung cancer.
D. Cortinovis, A. Leonetti, Alessandro Morabito, L. Sala, Marcello Tiseo   +4 more
semanticscholar   +1 more source

Cucurbitacin E inhibits the Yes‑associated protein signaling pathway and suppresses brain metastasis of human non‑small cell lung cancer in a murine model. [PDF]

, 2019
Human non‑small cell lung cancer (NSCLC) is associated with an extremely poor prognosis especially for the 40% of patients who develop brain metastasis, and few treatment strategies exist.
Hsu, Ping-Chih, Jablons, David M, Liu, Shu, Tian, Bo, Urisman, Anatoly, Wang, Yu-Cheng, Xu, Zhidong, Yang, Cheng-Ta, Yang, Yi-Lin, You, Liang   +9 more
core  

Quantification of afatinib, alectinib, crizotinib and osimertinib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry; focusing on the stability of osimertinib [PDF]

, 2019
The development and full validation of a sensitive and selective ultra-performance liquid chromatography/ tandem mass spectrometry (UPLC–MS/MS) method are described for the simultaneous analysis of afatinib, alectinib, crizotinib and osimertinib in ...
Bruijn, P.J. (Peter) de, Koolen, S.L.W. (Stijn), Lam, M.H. (Mei), Mathijssen, A.H.J. (Ron), Veerman, GDM   +4 more
core   +1 more source

Solubility, pH-Solubility Profile, pH-Rate Profile, and Kinetic Stability of the Tyrosine Kinase Inhibitor, Alectinib

Pharmaceuticals
Alectinib HCl (ALBHCl) is a tyrosine kinase inhibitor used for non-small cell lung carcinoma (NSCLC). The aim of this study is to unlock some of the physicochemical properties of ALBHCL that serve as a database for any future studies.
Dheyaa Tohma Madlool, I. Al-Ani, Tha'er Ata, W. A. Dayyih   +3 more
semanticscholar   +1 more source